{"status": "OK", "response": {"docs": [{"type_of_material": "Summary", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "LEAD: International A2-9", "headline": {"main": "NEWS SUMMARY"}, "abstract": null, "print_page": "2", "word_count": 1161, "_id": "4fd1b08f8eb7c8105d6d1908", "snippet": "LEAD:    International    A2-9", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1990/09/28/nyregion/news-summary-476690.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "NO INDEX TERMS"}], "byline": null, "document_type": "article", "pub_date": "1990-09-28T00:00:00Z", "section_name": "New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "LEAD: A controversy over Clozaril, an effective but costly drug for the hardest-to-treat symptoms of schizophrenia, has heated up, with the Food and Drug Administration requesting a labeling change that would stop the exclusive way the drug is sold. It is now marketed only through one health company, which administers a required weekly blood test.", "headline": {"main": "Outcry Grows Over Method of Selling New Drug", "kicker": "HEALTH"}, "abstract": null, "print_page": "9", "word_count": 974, "_id": "4fd1b0968eb7c8105d6d1e69", "snippet": "LEAD: A controversy over Clozaril, an effective but costly drug for the hardest-to-treat symptoms of schizophrenia, has heated up, with the Food and Drug Administration requesting a labeling change that would stop the exclusive way the drug is sold....", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1990/09/27/us/health-outcry-grows-over-method-of-selling-new-drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "HEALTH PAGE (NYT)"}, {"name": "organizations", "value": "CAREMARK INC"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "SANDOZ CORP"}, {"name": "subject", "value": "SCHIZOPHRENIA"}, {"name": "subject", "value": "ANTITRUST ACTIONS AND LAWS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "AGRANULOCYTOSIS"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Daniel", "lastname": "GOLEMAN"}], "original": "By DANIEL GOLEMAN"}, "document_type": "article", "pub_date": "1990-09-27T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "LEAD: DOCTORS are showing a cautious resurgence of interest in giving more consideration to their patients' racial or ethnic backgrounds when diagnosing and treating illnesses.", "headline": {"main": "Uneasy Doctors Add Race-Consciousness to Diagnostic Tool"}, "abstract": null, "print_page": "1", "word_count": 2108, "_id": "4fd1a5188eb7c8105d6bdbd9", "snippet": "LEAD: DOCTORS are showing a cautious resurgence of interest in giving more consideration to their patients' racial or ethnic backgrounds when diagnosing and treating illnesses.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1990/09/25/science/uneasy-doctors-add-race-consciousness-to-diagnostic-tool.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "MINORITIES (ETHNIC, RACIAL, RELIGIOUS)"}, {"name": "subject", "value": "RACE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"firstname": "Warren", "middlename": "E.", "lastname": "LEARY", "rank": 1, "role": "reported", "organization": ""}], "original": "By WARREN E. LEARY"}, "document_type": "article", "pub_date": "1990-09-25T00:00:00Z", "section_name": "Science; Health"}], "meta": {"hits": 3, "offset": 0, "time": 68}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}